Thumped by the FDA, Accera’s attempt to do a serious Alzheimer’s PhIII ends with a flop
A couple of years after Accera fell afoul of the FDA for its “false and misleading” label for a brain food product marketed as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
